Deere & Company’s AstraZeneca AZN Stock Holding History

Deere & Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,395	Closed	-$880K	–	86
2016 Q3	$880K	Sell	13,395 -1,686	-11%	-$110K	0.05%	437
2016 Q2	$911K	Hold	15,081	–	–	0.05%	404
2016 Q1	$849K	Hold	15,081	–	–	0.04%	427
2015 Q4	$1.02M	Hold	15,081	–	–	0.06%	310
2015 Q3	$960K	Hold	15,081	–	–	0.06%	325
2015 Q2	$961K	Hold	15,081	–	–	0.05%	408
2015 Q1	$1.03M	Hold	15,081	–	–	0.06%	337
2014 Q4	$1.06M	Hold	15,081	–	–	0.06%	330
2014 Q3	$1.08M	Hold	15,081	–	–	0.06%	350
2014 Q2	$1.12M	Buy	15,081 +126	+0.8%	+$9.11K	0.06%	322
2014 Q1	$970K	Sell	14,955 -2,553	-15%	-$165K	0.06%	382
2013 Q4	$1.04M	Hold	17,508	–	–	0.05%	366
2013 Q3	$909K	Buy	17,508 +1,351	+8%	+$67.9K	0.05%	374
2013 Q2	$764K	Buy	+16,157	New	+$823K	0.05%	423

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Deere & Company's AZN Position: Q4 2016 in Review

Deere & Company sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 13,395 shares — an estimated $880K sold.

Deere & Company first reported a position in AZN in Q2 2013 and held it in 14 quarters. The position peaked at $1.12M in Q2 2014. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

Deere & Company reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
Deere & Company sold 13,395 AstraZeneca shares in Q4 2016, an estimated $880K.
Deere & Company first reported a position in AstraZeneca in Q2 2013 and held it in 14 quarters.
Deere & Company's AstraZeneca position peaked at $1.12M in Q2 2014.
450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.